Emjard™ M 12.5/500 is a combination tablet containing Empagliflozin 12.5 mg and Metformin Hydrochloride 500 mg, manufactured by Square Pharmaceuticals Ltd., Bangladesh. This oral medication is indicated for the management of type 2 diabetes mellitus in adults, particularly when diet, exercise, and metformin alone do not provide adequate glycemic control.